How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review

Vista sencilla de ítem
dc.contributor.authorTorres, Gabriel Fernando
dc.contributor.authorBonilla, Carlos Eduardo
dc.contributor.authorArrieta, Oscar
dc.contributor.orcidBuitrago, Giancarlo [https://orcid.org/0000-0002-7466-8244]
dc.contributor.orcidMalapelle, Umberto [https://orcid.org/0000-0003-3211-9957]
dc.contributor.orcidRolfo, Christian [https://orcid.org/0000-0002-5109-0267]
dc.contributor.orcidCardona, Andrés Felipe [https://orcid.org/0000-0003-3525-4126]
dc.date.accessioned2022-03-07T21:27:57Z
dc.date.available2022-03-07T21:27:57Z
dc.date.issued2021
dc.description.abstractenglishGiven the lack of a gold standard, the clinical usefulness of Comprehensive Genomic Profiling (CGP) has not been established. This systematic review aimed to evaluate evidence about the clinical benefit of CGP for patients with Non-small cell lung carcinoma (NSCLC). All controlled studies that evaluated the ability of CGP to detect actionable targets (ATs) reported increases in the number of samples with ATs. The frequency of ATs detected in uncontrolled case series ranged from 0.7 % for RET mutations to 45 % for EGFR mutations. The studies that evaluated therapies targeted to EGFR, ALK, ROS-1, MET, and RET mutations documented significant improvement in clinical outcomes. This review suggests that CGP tests may be clinically helpful for treating patients with NSCLC. Although current evidence is associated with a high risk of bias, the significant impact of NSCLC on individuals and society may justify the routine use of CGP testing for this disease.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.critrevonc.2021.103459
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1040-8428
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/7164
dc.language.isoeng
dc.publisherElsevier Ireland Ltdspa
dc.publisher.journalCritical Reviews in Oncology/Hematologyspa
dc.relation.ispartofseriesCritical Reviews in Oncology/Hematology, 1040-8428, Vol 166, 2021spa
dc.relation.urihttps://www.sciencedirect.com/science/article/abs/pii/S1040842821002468?via%3Dihub
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.localAcceso abiertospa
dc.subject.keywordsCompanion diagnosticsspa
dc.subject.keywordsPersonalized oncologyspa
dc.subject.keywordsNext-generation sequencingspa
dc.titleHow clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic reviewspa
dc.title.translatedHow clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic reviewspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.coarversionhttps://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer A systematic review.pdf
Tamaño:
979.32 KB
Formato:
Adobe Portable Document Format
Descripción:
How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer A systematic review
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos